Researchers at the US-based Georgetown University Medical Center claimed to have understood how a cancer drug functions in the brains of patients with Parkinson’s disease.
Eli Lilly and Company has announced that its Phase 3 RELAY study of CYRAMZA (ramucirumab) met its primary endpoint of progression-free survival (PFS), demonstrating a statistically significant improvement in the time patients lived without their cancer growing or spreading after starting treatment.
Tenax Therapeutics announced that the first patient has been randomized for its phase 2 trial designed to evaluate levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF).
Gilead Sciences has announced findings from two studies that support the further development of GS-6207, a novel, selective, first-in-class inhibitor of HIV-1 capsid function, for potential future use as part of long-acting HIV combination therapy.
ViiV Healthcare presented comprehensive 48-week data from the ATLAS (Antiretroviral Therapy as Long-Acting Suppression) and FLAIR (First Long-Acting Injectable Regimen) pivotal phase III studies of the novel, investigational, long-acting regimen of cabotegravir and rilpivirine.
A second person has experienced sustained remission from HIV-1 after ceasing treatment, reports a paper led by UCL and Imperial College London.
Novo Nordisk’s Ozempic (semaglutide), in combination to SGLT-2 inhibitor (SGLT-2i) therapy, met the primary endpoint in a phase 3 trial in patients with type 2 diabetes.
Novartis announced new data in 441 Chinese patients with moderate to severe plaque psoriasis from a Phase III study investigating the efficacy and safety of Cosentyx (secukinumab).
Verona Pharma said that the first part of a two-part phase 2 trial of ensifentrine in a dry powder inhaler (DPI) formulation for the treatment of moderate-to-severe chronic obstructive pulmonary disease (COPD) has yielded positive interim efficacy and safety data.
Shield Therapeutics said that its oral ferric iron therapy Feraccru proved to be non-inferior to Ferinject (ferric carboxymaltose or FCM), a widely used intravenously delivered iron replacement therapy, in the AEGIS-H2H non-inferiority study.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.